OBJECTIVE: Statins inhibit cholesterol synthesis but can upregulate cholesterol absorption, with higher doses producing larger effects. Ezetimibe inhibits cholesterol absorption but also upregulates synthesis. We tested whether ezetimibe added to on-going statin therapy would be most effective in lowering LDL-cholesterol (LDL-C) in subjects on high-potency statins and whether these effects would be related to alterations in cholesterol absorption (β-sitosterol) and synthesis (lathosterol) markers. METHODS:Hypercholesterolemic subjects (n = 874) on statins receivedezetimibe 10 mg/day. Plasma lipids, lathosterol, and β-sitosterol were measured at baseline and on treatment. Subjects were divided into low- (n = 133), medium- (n = 582), and high- (n = 159) statin potency groups defined by predicted LDL-C-lowering effects of each ongoing statin type and dose (reductions of ~20-30%, ~31-45%, or ~46-55%, respectively). RESULTS: The high-potency group had significantly lower baseline lathosterol (1.93 vs. 2.58 vs. 3.17 μmol/l; p < 0.001) and higher baseline β-sitosterol values (6.21 vs. 4.58 vs. 4.51 μmol/l, p < 0.001) than medium-/low-potency groups. Ezetimibe treatment in the high-potency group produced significantly greater reductions from baseline in LDL-C than medium-/low-potency groups (-29.1% vs. -25.0% vs. -22.7%; p < 0.001) when evaluating unadjusted data. These effects and group differences were significantly (p < 0.05) related to greater β-sitosterol reductions and smaller lathosterol increases. However, LDL-C reduction differences between groups were no longer significant after controlling for placebo effects, due mainly to modest LDL-C lowering by placebo in the high-potency group. CONCLUSION: Patients on high-potency statins have the lowest levels of cholesterol synthesis markers and the highest levels of cholesterol absorption markers at baseline, and the greatest reduction in absorption markers and the smallest increases in synthesis markers with ezetimibe addition. Therefore, such patients may be good candidates for ezetimibe therapy if additional LDL-C lowering is needed.
RCT Entities:
OBJECTIVE: Statins inhibit cholesterol synthesis but can upregulate cholesterol absorption, with higher doses producing larger effects. Ezetimibe inhibits cholesterol absorption but also upregulates synthesis. We tested whether ezetimibe added to on-going statin therapy would be most effective in lowering LDL-cholesterol (LDL-C) in subjects on high-potency statins and whether these effects would be related to alterations in cholesterol absorption (β-sitosterol) and synthesis (lathosterol) markers. METHODS:Hypercholesterolemic subjects (n = 874) on statins received ezetimibe 10 mg/day. Plasma lipids, lathosterol, and β-sitosterol were measured at baseline and on treatment. Subjects were divided into low- (n = 133), medium- (n = 582), and high- (n = 159) statin potency groups defined by predicted LDL-C-lowering effects of each ongoing statin type and dose (reductions of ~20-30%, ~31-45%, or ~46-55%, respectively). RESULTS: The high-potency group had significantly lower baseline lathosterol (1.93 vs. 2.58 vs. 3.17 μmol/l; p < 0.001) and higher baseline β-sitosterol values (6.21 vs. 4.58 vs. 4.51 μmol/l, p < 0.001) than medium-/low-potency groups. Ezetimibe treatment in the high-potency group produced significantly greater reductions from baseline in LDL-C than medium-/low-potency groups (-29.1% vs. -25.0% vs. -22.7%; p < 0.001) when evaluating unadjusted data. These effects and group differences were significantly (p < 0.05) related to greater β-sitosterol reductions and smaller lathosterol increases. However, LDL-C reduction differences between groups were no longer significant after controlling for placebo effects, due mainly to modest LDL-C lowering by placebo in the high-potency group. CONCLUSION:Patients on high-potency statins have the lowest levels of cholesterol synthesis markers and the highest levels of cholesterol absorption markers at baseline, and the greatest reduction in absorption markers and the smallest increases in synthesis markers with ezetimibe addition. Therefore, such patients may be good candidates for ezetimibe therapy if additional LDL-C lowering is needed.
Authors: Thomas A Pearson; Margo A Denke; Patrick E McBride; Wendy P Battisti; Russell A Gazzara; William E Brady; Joanne Palmisano Journal: Mayo Clin Proc Date: 2006-09 Impact factor: 7.616
Authors: Ioanna Gouni-Berthold; Heiner K Berthold; Helena Gylling; Maarit Hallikainen; Eleni Giannakidou; Sebastian Stier; Yon Ko; Dilip Patel; Anne K Soutar; Udo Seedorf; Christos S Mantzoros; Jogchum Plat; Wilhelm Krone Journal: Atherosclerosis Date: 2007-11-05 Impact factor: 5.162
Authors: Susan G Lakoski; Fang Xu; Gloria L Vega; Scott M Grundy; Manisha Chandalia; Chun Lam; Robert S Lowe; Michael E Stepanavage; Thomas A Musliner; Jonathan C Cohen; Helen H Hobbs Journal: J Clin Endocrinol Metab Date: 2009-12-04 Impact factor: 5.958
Authors: Peter H Jones; Michael H Davidson; Evan A Stein; Harold E Bays; James M McKenney; Elinor Miller; Valerie A Cain; James W Blasetto Journal: Am J Cardiol Date: 2003-07-15 Impact factor: 2.778
Authors: Thomas M van Himbergen; Nirupa R Matthan; Nancy A Resteghini; Seiko Otokozawa; Masumi Ai; Evan A Stein; Peter H Jones; Ernst J Schaefer Journal: J Lipid Res Date: 2008-11-30 Impact factor: 5.922
Authors: L Jakulj; M N Vissers; A K Groen; B A Hutten; D Lutjohann; E P Veltri; J J P Kastelein Journal: J Lipid Res Date: 2009-10-14 Impact factor: 5.922
Authors: Stefania Lamon-Fava; Margaret R Diffenderfer; P Hugh R Barrett; Aaron Buchsbaum; Nirupa R Matthan; Alice H Lichtenstein; Gregory G Dolnikowski; Katalin Horvath; Bela F Asztalos; Valeria Zago; Ernst J Schaefer Journal: J Lipid Res Date: 2007-05-27 Impact factor: 5.922
Authors: Gerd Assmann; Frank Kannenberg; Dena R Ramey; Thomas A Musliner; Stephen W Gutkin; Enrico P Veltri Journal: Curr Med Res Opin Date: 2008-01 Impact factor: 2.580
Authors: Matthew Peach; Ren Xu; Dan Fitzpatrick; Lisa Hamilton; Ransi Somaratne; Robert Scott; Scott M Wasserman; C Stephen Djedjos Journal: J Lipid Res Date: 2016-10-05 Impact factor: 5.922
Authors: Muhammad Shahdaat Bin Sayeed; Selim Muhammad Rezaul Karim; Tasnuva Sharmin; Mohammed Monzur Morshed Journal: Medicines (Basel) Date: 2016-11-15